Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy

A controlled trial

Paolo Vercellini, Laura Trespìdi, Barbara Zaina, Sarah Vicentini, Giovanna Stellato, Pier Giorgio Crosignani

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective: To ascertain whether adjuvant gonadotropin-releasing hormone (GnRH) agonist therapy decreases blood loss during abdominal myomectomy. Design: Randomized controlled trial. Setting: Academic reproductive surgery center. Patient(s): One hundred premenopausal women requiring first-line conservative surgery for symptomatic intramural or subserous fibroids. Intervention(s): Eight weeks of treatment with depot triptorelin before myomectomy or immediate surgery. Main outcome measure(s): Intraoperative blood loss, operating time, degree of difficulty of the procedure, and short-term rate of fibroid recurrence. Result(s): Mean (±SD) intraoperative blood loss was 265 ± 181 mL in triptorelin recipients and 296 ± 204 in patients who had immediate surgery (mean difference, -31 mL [95% CI, -108 to 46 mL]). No significant differences were observed in blood loss according to uterine volume, number of fibroids removed, or total length of myometrial incisions. Most procedures in either group were of routine difficulty. On ultrasonography 6 months after myomectomy, four women in the GnRH agonist group and one in the immediate surgery group had tumor recurrence. Conclusion(s): Treatment with a GnRH agonist before abdominal myomectomy has no significant effect on intraoperative blood loss. Thus, systematic use of medical therapy before abdominal myomectomy does not seem to be justified.

Original languageEnglish
Pages (from-to)1390-1395
Number of pages6
JournalFertility and Sterility
Volume79
Issue number6
DOIs
Publication statusPublished - Jun 1 2003

Fingerprint

Uterine Myomectomy
Gonadotropin-Releasing Hormone
Leiomyoma
Triptorelin Pamoate
Therapeutics
Recurrence
Ultrasonography
Randomized Controlled Trials
Outcome Assessment (Health Care)

Keywords

  • Conservative surgery
  • Fibroid
  • GnRH agonists
  • Infertility
  • Menorrhagia
  • Myomectomy
  • Uterine leiomyoma

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy : A controlled trial. / Vercellini, Paolo; Trespìdi, Laura; Zaina, Barbara; Vicentini, Sarah; Stellato, Giovanna; Crosignani, Pier Giorgio.

In: Fertility and Sterility, Vol. 79, No. 6, 01.06.2003, p. 1390-1395.

Research output: Contribution to journalArticle

Vercellini, Paolo ; Trespìdi, Laura ; Zaina, Barbara ; Vicentini, Sarah ; Stellato, Giovanna ; Crosignani, Pier Giorgio. / Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy : A controlled trial. In: Fertility and Sterility. 2003 ; Vol. 79, No. 6. pp. 1390-1395.
@article{5e17024b7dd44cbc9fa3c496444d874a,
title = "Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy: A controlled trial",
abstract = "Objective: To ascertain whether adjuvant gonadotropin-releasing hormone (GnRH) agonist therapy decreases blood loss during abdominal myomectomy. Design: Randomized controlled trial. Setting: Academic reproductive surgery center. Patient(s): One hundred premenopausal women requiring first-line conservative surgery for symptomatic intramural or subserous fibroids. Intervention(s): Eight weeks of treatment with depot triptorelin before myomectomy or immediate surgery. Main outcome measure(s): Intraoperative blood loss, operating time, degree of difficulty of the procedure, and short-term rate of fibroid recurrence. Result(s): Mean (±SD) intraoperative blood loss was 265 ± 181 mL in triptorelin recipients and 296 ± 204 in patients who had immediate surgery (mean difference, -31 mL [95{\%} CI, -108 to 46 mL]). No significant differences were observed in blood loss according to uterine volume, number of fibroids removed, or total length of myometrial incisions. Most procedures in either group were of routine difficulty. On ultrasonography 6 months after myomectomy, four women in the GnRH agonist group and one in the immediate surgery group had tumor recurrence. Conclusion(s): Treatment with a GnRH agonist before abdominal myomectomy has no significant effect on intraoperative blood loss. Thus, systematic use of medical therapy before abdominal myomectomy does not seem to be justified.",
keywords = "Conservative surgery, Fibroid, GnRH agonists, Infertility, Menorrhagia, Myomectomy, Uterine leiomyoma",
author = "Paolo Vercellini and Laura Tresp{\`i}di and Barbara Zaina and Sarah Vicentini and Giovanna Stellato and Crosignani, {Pier Giorgio}",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S0015-0282(03)00362-5",
language = "English",
volume = "79",
pages = "1390--1395",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy

T2 - A controlled trial

AU - Vercellini, Paolo

AU - Trespìdi, Laura

AU - Zaina, Barbara

AU - Vicentini, Sarah

AU - Stellato, Giovanna

AU - Crosignani, Pier Giorgio

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Objective: To ascertain whether adjuvant gonadotropin-releasing hormone (GnRH) agonist therapy decreases blood loss during abdominal myomectomy. Design: Randomized controlled trial. Setting: Academic reproductive surgery center. Patient(s): One hundred premenopausal women requiring first-line conservative surgery for symptomatic intramural or subserous fibroids. Intervention(s): Eight weeks of treatment with depot triptorelin before myomectomy or immediate surgery. Main outcome measure(s): Intraoperative blood loss, operating time, degree of difficulty of the procedure, and short-term rate of fibroid recurrence. Result(s): Mean (±SD) intraoperative blood loss was 265 ± 181 mL in triptorelin recipients and 296 ± 204 in patients who had immediate surgery (mean difference, -31 mL [95% CI, -108 to 46 mL]). No significant differences were observed in blood loss according to uterine volume, number of fibroids removed, or total length of myometrial incisions. Most procedures in either group were of routine difficulty. On ultrasonography 6 months after myomectomy, four women in the GnRH agonist group and one in the immediate surgery group had tumor recurrence. Conclusion(s): Treatment with a GnRH agonist before abdominal myomectomy has no significant effect on intraoperative blood loss. Thus, systematic use of medical therapy before abdominal myomectomy does not seem to be justified.

AB - Objective: To ascertain whether adjuvant gonadotropin-releasing hormone (GnRH) agonist therapy decreases blood loss during abdominal myomectomy. Design: Randomized controlled trial. Setting: Academic reproductive surgery center. Patient(s): One hundred premenopausal women requiring first-line conservative surgery for symptomatic intramural or subserous fibroids. Intervention(s): Eight weeks of treatment with depot triptorelin before myomectomy or immediate surgery. Main outcome measure(s): Intraoperative blood loss, operating time, degree of difficulty of the procedure, and short-term rate of fibroid recurrence. Result(s): Mean (±SD) intraoperative blood loss was 265 ± 181 mL in triptorelin recipients and 296 ± 204 in patients who had immediate surgery (mean difference, -31 mL [95% CI, -108 to 46 mL]). No significant differences were observed in blood loss according to uterine volume, number of fibroids removed, or total length of myometrial incisions. Most procedures in either group were of routine difficulty. On ultrasonography 6 months after myomectomy, four women in the GnRH agonist group and one in the immediate surgery group had tumor recurrence. Conclusion(s): Treatment with a GnRH agonist before abdominal myomectomy has no significant effect on intraoperative blood loss. Thus, systematic use of medical therapy before abdominal myomectomy does not seem to be justified.

KW - Conservative surgery

KW - Fibroid

KW - GnRH agonists

KW - Infertility

KW - Menorrhagia

KW - Myomectomy

KW - Uterine leiomyoma

UR - http://www.scopus.com/inward/record.url?scp=0038511958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038511958&partnerID=8YFLogxK

U2 - 10.1016/S0015-0282(03)00362-5

DO - 10.1016/S0015-0282(03)00362-5

M3 - Article

VL - 79

SP - 1390

EP - 1395

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 6

ER -